CGEN Stock Overview
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Compugen Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.08 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$4.43 |
| Beta | 0 |
| 1 Month Change | -2.18% |
| 3 Month Change | -20.06% |
| 1 Year Change | -36.97% |
| 3 Year Change | -16.43% |
| 5 Year Change | -89.34% |
| Change since IPO | -38.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| CGEN | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 2.7% |
| 1Y | -37.0% | -11.3% | 43.1% |
Return vs Industry: CGEN underperformed the IL Biotechs industry which returned -11.3% over the past year.
Return vs Market: CGEN underperformed the IL Market which returned 43.1% over the past year.
Price Volatility
| CGEN volatility | |
|---|---|
| CGEN Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.7% |
Stable Share Price: CGEN's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: CGEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 74 | Anat Cohen-Dayag | cgen.com |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
Compugen Ltd. Fundamentals Summary
| CGEN fundamental statistics | |
|---|---|
| Market cap | ₪483.02m |
| Earnings (TTM) | -₪49.70m |
| Revenue (TTM) | ₪96.94m |
Is CGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEN income statement (TTM) | |
|---|---|
| Revenue | US$27.59m |
| Cost of Revenue | US$8.23m |
| Gross Profit | US$19.36m |
| Other Expenses | US$33.51m |
| Earnings | -US$14.14m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 70.18% |
| Net Profit Margin | -51.27% |
| Debt/Equity Ratio | 0% |
How did CGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 13:48 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Compugen Ltd. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Vernon Bernardino | FBR Capital Markets & Co. |